Description: Neurocrine Biosciences, Inc. engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. It develops drugs for endometriosis, tardive dyskinesia, uterine fibroids, stress-related disorders, pain, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. The company's products in clinical development include Elagolix, a Phase III drug for endometriosis; Vesicular Monoamine Transporter 2 Inhibitor (VMAT2), a Phase II drug for movement disorders; CRF2 Peptide Agonist, a Phase II drug for cardiovascular diseases; CRF1 Antagonist, a Phase II drug for stress-related disorders; and Elagolix, a Phase II drug for uterine fibroids. Its research programs comprise G Protein-Coupled Receptor 119 (GPR119) for type II diabetes; VMAT2 for schizophrenia; gonadotropin-releasing hormone (GnRH) Antagonists for men's and women's health, and oncology; Antiepileptic Drugs for epilepsy, essential tremor, and pain; and G Protein-Coupled Receptors for other conditions. The company has collaborations with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women's and men's health; Boehringer Ingelheim International GmbH to research, develop, and commercialize small molecule GPR119 agonists for the treatment of Type II diabetes and other indications; and Dainippon Sumitomo Pharma Co. Ltd. to develop and commercialize indiplon in Japan. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.
Home Page: www.neurocrine.com
NBIX Technical Analysis
12780 El Camino Real
San Diego,
CA
92130
United States
Phone:
858 617 7600
Officers
| Name | Title |
|---|---|
| Dr. Kevin C. Gorman Ph.D. | CEO & Director |
| Mr. Matthew C. Abernethy | Chief Financial Officer |
| Dr. Jude Onyia Ph.D. | Chief Scientific Officer |
| Mr. Eric S. Benevich | Chief Commercial Officer |
| Dr. Eiry Wyn Roberts M.D. | Chief Medical Officer |
| Dr. Dimitri E. Grigoriadis | Chief Research Officer |
| Jane Sorensen | Head of Investor Relations |
| Mr. Darin M. Lippoldt | Chief Legal Officer & Corp. Sec. |
| Mr. Kyle W. Gano | Chief Bus. Devel. and Strategy Officer |
| Ms. Julie S. Cooke | Chief HR Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 28.8184 |
|---|---|
| Trailing PE: | 182.95 |
| Price-to-Book MRQ: | 7.2969 |
| Price-to-Sales TTM: | 8.078 |
| IPO Date: | 1996-05-23 |
| Fiscal Year End: | December |
| Full Time Employees: | 1150 |